Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542236 | 0.98 | PDE4A (0.41) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL9297279 | 0.98 | PDE4A (0.41) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL18322325 | 0.98 | PDE4A (0.41) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL1110835 | 0.98 | PDE4A (0.41) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL6686316 | 0.96 | PDE4A (0.40) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL5484358 | 0.93 | PDE4A (0.44) | PDE4ATSHRCYP2C9PGDGPR84 | |
| SCHEMBL27668989 | 0.87 | FFAR1 (0.39) | PDE4AFFAR1FFAR4PTPN1 | |
| SCHEMBL27844422 | 0.87 | FFAR1 (0.39) | PDE4AFFAR1FFAR4PTPN1 | |
| SCHEMBL28394802 | 0.87 | FFAR1 (0.39) | PDE4AFFAR1FFAR4PTPN1 | |
| SCHEMBL27668981 | 0.87 | FFAR1 (0.39) | PDE4AFFAR1FFAR4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20020010351-A1 | Lipoxin compounds and their use in treating cell proliferative disorders | SERHAN CHARLES N (US) | 2002-01-24 | — | — | US | disclosed |
| US-6316648-B1 | PURIFIED 5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID; ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-11-13 | — | — | US | disclosed |
| US-20010031882-A1 | Lipoxin compounds and their use in treating cell proliferative disorders | SERHAN CHARLES N (US) | 2001-10-18 | — | — | US | disclosed |
| US-6048897-A | ALSO ANTICARCINOGENIC OR ANTITUMOR AGENTS | BRIGHAM AND WOMEN'S HOSPITAL (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0927150-A1 | LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011049-A1 | LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5648512-A | Lipoxin compounds | BRIGHAM & WOMENS HOSPITAL (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0703897-A1 | LIPOXIN COMPOUNDS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5441951-A | Lipoxin compounds | BRIGHAM & WOMEN'S HOSPITAL (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1994029262-A1 | LIPOXIN COMPOUNDS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-20020010351-A1 | Lipoxin compounds and their use in treating cell proliferative disorders | ALOX15, ALOX12, ALOX15B | PDE4A 2581/4885TSHR 2585/4885CYP2C9 4457/4885 |
| US-20010031882-A1 | Lipoxin compounds and their use in treating cell proliferative disorders | ALOX15, ALOX12, ALOX15B | PDE4A 2581/4885TSHR 2585/4885CYP2C9 4457/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.